Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter September 26, 2016

Detection of BRAFV600K mutant tumor-derived DNA in the pleural effusion from a patient with metastatic melanoma

  • Kaori Sakaizawa , Atsuko Ashida , Hisashi Uhara and Ryuhei Okuyama EMAIL logo
  1. Author contributions: All the authors accept responsibility for the content of this manuscript and have approved its submission.

  2. Research funding: This study was supported by a grant from JSPS KAKENHI 15K19685.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Menzies AM, Long GV. Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol 2014;15:e371–81.10.1016/S1470-2045(14)70072-5Search in Google Scholar

2. Ashida A, Sakaizawa K, Mikoshiba A, Uhara H, Okuyama R. Quantitative analysis of the BRAF mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR. Int J Clin Oncol 2016, Epub ahead of print.10.1007/s10147-016-0976-ySearch in Google Scholar PubMed

3. Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, et al. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin Cancer Res 2016;22:567–74.10.1158/1078-0432.CCR-15-0321Search in Google Scholar PubMed

4. Tsao SC, Weiss J, Hudson C, Christophi C, Cebon J, Behren A, et al. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci Rep 2015;5:11198.10.1038/srep11198Search in Google Scholar PubMed PubMed Central

5. Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014;20:430–5.10.1038/nm.3511Search in Google Scholar PubMed

6. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999;64:218–24.10.1086/302205Search in Google Scholar PubMed PubMed Central

7. Li Y, Pan W, Connolly ID, Reddy S, Nagpal S, Quake S, et al. Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. J Neurooncol 2016;128:93–100.10.1007/s11060-016-2081-5Search in Google Scholar PubMed PubMed Central

8. Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer 2012;106:939–46.10.1038/bjc.2012.12Search in Google Scholar PubMed PubMed Central

9. Ashida A, Uhara H, Kiniwa Y, Oguchi M, Murata H, Goto Y, et al. Assessment of BRAF and KIT mutations in Japanese melanoma patients. J Dermatol Sci 2012;66:240–2.10.1016/j.jdermsci.2012.03.005Search in Google Scholar PubMed

10. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012;30:2522–9.10.1200/JCO.2011.41.2452Search in Google Scholar PubMed

Received: 2016-7-16
Accepted: 2016-8-15
Published Online: 2016-9-26
Published in Print: 2017-3-1

©2017 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 19.3.2024 from https://www.degruyter.com/document/doi/10.1515/cclm-2016-0634/html
Scroll to top button